$1.76
▲ +1.1% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial
Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
Overview
52-week range
$1.54
$5.50
6% of range
Avg surprise (last 2)
+21.5%
Avg reaction (last 2)
+3.2%
50% positive
Latest IV / EM
988%
EM ±41.3% · $2 · Jul 10
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 15, 2026 | Mar/2026 | $-0.63 | — | — | -96.9% | -3.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.37 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.32 | $-0.36 | +11.1% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.32 | $-0.47 | +31.9% | — | +9.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.97 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.44 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.72 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.63 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.07 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.44 | -$0.32 | -37.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | — | — | $0 | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-18M | — | $-7M | $-6M | $-6M | — | $-4M | $-8M |
| Net income | $-18M | — | $-7M | $-6M | $-6M | — | $-13M | $-5M |
| EPS (diluted) | $-0.63 | — | $-0.37 | $-0.32 | $-0.32 | — | $-0.97 | $-0.44 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $14M | $20M | $15M | $17M | $22M | $11M | $13M | $4M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | — | — | — | — | — | — | — | — |
| Total assets | $16M | $21M | $17M | $21M | $27M | $14M | $14M | $5M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $13M | $4M | $4M | $3M | $3M | $5M | $7M | $7M |
| Total equity | $3M | $17M | $13M | $18M | $24M | $9M | $7M | $-2M |